| Literature DB >> 35072076 |
Federica Di Guardo1, Christophe Blockeel2, Michel De Vos2, Marco Palumbo1, Nikolaos Christoforidis3, Herman Tournaye2, Panagiotis Drakopoulos4.
Abstract
About 20% of women undergoing in vitro fertilization struggle with poor ovarian response, indicating a poor prognosis related to low response following ovarian stimulation. Indeed, poor ovarian response, that is associated with both high cancelation rates and low live birth rates, still represents one of the most important therapeutic challenges in in vitro fertilization. In this context, natural cycle/modified natural cycle-in vitro fertilization, as a 'milder' approach, could be a reasonable alternative to high-dose/conventional ovarian stimulation in poor ovarian responders, with the aim to retrieve a single oocyte with better characteristics that may result in a single top-quality embryo, transferred to a more receptive endometrium. Moreover, modified natural cycle-in vitro fertilization may be cost-effective because of the reduced gonadotropin consumption. Several studies have been published during the last 20 years reporting conflicting results regarding the use of natural cycle/modified natural cycle-in vitro fertilization in women with poor ovarian response; however, while most of the studies concluded that mild stimulation regimens, including natural cycle/modified natural cycle-in vitro fertilization, have low, but acceptable success rates in this difficult group of patients, others did not replicate these findings. The aim of this narrative review is to appraise the current evidence regarding the use of natural cycle/modified natural cycle-in vitro fertilization in poor ovarian responders.Entities:
Keywords: IVF; modified natural cycle; ovarian stimulation; poor ovarian responders
Year: 2022 PMID: 35072076 PMCID: PMC8771731 DOI: 10.1177/26334941211062026
Source DB: PubMed Journal: Ther Adv Reprod Health ISSN: 2633-4941
Retrospective studies investigating the role of natural cycle/MNC-IVF in PORs.
| Author | Year | Study design | Inclusion criteria | Total | Investigation group | Comparison group(s) | Results |
|---|---|---|---|---|---|---|---|
| Elizur | 2005 | Retrospective | Poor responders defined as ⩽4 oocytes obtained at OPU or an E2 level < 1000 pg/ml on the day of hCG administration | 433 patients | 52 MNC-IVF cycles with antagonist | 200 cycles of conventional ovarian stimulation with antagonist | IR and PR did not statically differ between the groups |
| Ata | 2008 | Retrospective | Women who underwent a previous unsuccessful cycle in which <5 oocytes had been collected at OPU | 304 patients | 30 women undergoing natural cycles | 54 women undergoing protocol with gonadotropin only | PR did not statically differ between the groups |
| Polyzos | 2012 | Retrospective | Women undergoing natural cycle IVF without any ovarian stimulation or use of GnRH antagonist | 164 patients (469 cycles) | 390 cycles with women fulfilling the BC undergoing natural cycle IVF | 79 cycles with women, classified as normal responders, undergoing natural cycle IVF | LBR was significantly lower in PORs group |
| Kedem | 2014 | Retrospective | Patients with poor ovarian response defined according to the BC, who underwent a subsequent MNC-IVF within 3 months of the previous failed conventional IVF/ICSI cycle | 111 patients | 111 women fulfilling the BC undergoing MNCs | Failed conventional IVF/ICSI cycle in the same patients | LBR and PR was significantly lower in MNC-IVF group |
| Lainas | 2015 | Retrospective | Women fulfilling the BC for the definition of poor ovarian response | 242 patients | 106 women treated with MNC-IVF | 164 women treated with high-dose FSH antagonist protocol | LBR was significantly higher in MNC-IVF group |
| Drakopoulos | 2019 | Retrospective | Advanced-age poor responders women fulfilling the BC | 476 patients | 189 women treated with MNC-IVF | 287 women treated with high-dose gonadotropins antagonist protocol | OPR per patient was significantly higher in women treated with high-dose gonadotropins |
| Liu | 2021 | Retrospective | Women fulfilling the BC for the definition of poor ovarian response | 699 patients | 374 patients (733 cycles) treated with minimal ovarian stimulation including natural cycles | 325 women treated with GnRH antagonist cycles (325 cycles) | CLBR did not statistically differ between the two groups |
BC, Bologna criteria; CLBR, cumulative live birth rate; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; ICSI, intracytoplasmic sperm injection; IR, implantation rate; IVF, in vitro fertilization; LBR, live birth rate; MNC-IVF, modified natural cycle–in vitro fertilization; n, number; OPR, ongoing pregnancy rate; OPU, oocytes pick up; PORs, poor ovarian responders; PR, pregnancy rate.
Randomized controlled studies investigating the role of natural cycle/MNC-IVF in PORs.
| Author | Year | Study design | Inclusion criteria | Total | Investigation group | Comparison group(s) | Results |
|---|---|---|---|---|---|---|---|
| Morgia | 2004 | RCT | Women ⩽ 43 years who underwent a previous IVF cycle with poor response considered as three or fewer follicles recruited, or cycle canceled because of no follicle activation. | 129 patients | 59 women undergoing 114 attempts with natural cycle IVF | 70 women undergoing 101 attempts of IVF with ovarian stimulation with the microdose GnRH analog flare protocol | PR was similar between the groups both per cycle and per transfer, IR was significantly higher in the natural cycle IVF group |
| Kim | 2009 | RCT | Women who underwent a previous IVF/ICSI cycle and failed to produce three or fewer follicles | 90 patients | 45 women undergoing IVF/ICSI with minimal stimulation | 45 women undergoing IVF/ICSI with GnRH antagonist multiple-dose protocol | PR did not statically differ between the groups |
GnRH, gonadotropin-releasing hormone; IR, implantation rate; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; MNC-IVF, modified natural cycle–in vitro fertilization; n, number; PORs, poor ovarian responders; PR, pregnancy rate; RCT, randomized controlled trial.